New stage in evolution of drug treatment of pleural mesothelioma-Reference-Cited by-同舟云学术

New stage in evolution of drug treatment of pleural mesothelioma

Published:2022-11-23 Issue:26 Volume: Page:27-30
ISSN:2078-5631
Container-title:Medical alphabet
language:
Short-container-title:Medicinskij alfavit

Author:

Barbolina T. D.¹^ORCID,Bagrova S. G.²^ORCID

Affiliation:

1. National Medical Research Centre of Oncology n. a. N. N. Blokhin; Moscow State University of Medicine and Dentistry n. a. A. I. Evdokimov

2. National Medical Research Centre of Oncology n. a. N. N. Blokhin

Abstract

For a long time, cytostatic therapy practically does not increase life expectancy than up to 18 months. The article describes the latest advances in the development of drug treatment of pleural mesothelioma and the results of the CheckMate‑743 trial, which are a turning point in the development of drug treatment for malignant unresectable pleural mesothelioma.

Publisher

Alfmed LLC

Subject

Materials Chemistry,Economics and Econometrics,Media Technology,Forestry

Reference31 articles.

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–2644.

2. Kindler HL, Ismaila N, Armato SG III, et al: Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018; 36: 1343–1373.

3. Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3: 756–63.

4. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19: 370–3.

5. Dudek AZ, Wang X, Gu L, et al: Randomized phase 2 study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first line chemotherapy: Cancer and Leukemia Group B30901 (Alliance). Clin Lung Cancer 2020; 21: 553–561.